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Background. Poor tolerance and adverse drug reactions are main reasons for discontinuation of antiretroviral
therapy (ART). Identifying predictors of ART discontinuation is a priority in HIV care.
Methods. A genetic association study in an observational cohort to evaluate the association of
pharmacogenetic markers with time to treatment discontinuation during the first year of ART. Analysis included
577 treatment-naive individuals initiating tenofovir (n 5 500) or abacavir (n 5 77), with efavirenz (n 5 272),
lopinavir/ritonavir (n 5 184), or atazanavir/ritonavir (n 5 121). Genotyping included 23 genetic markers in 15
genes associated with toxicity or pharmacokinetics of the study medication. Rates of ART discontinuation between
groups with and without genetic risk markers were assessed by survival analysis using Cox regression models.
Results. During the first year of ART, 190 individuals (33%) stopped 1 or more drugs. For efavirenz and
atazanavir, individuals with genetic risk markers experienced higher discontinuation rates than individuals without
(71.15% vs 28.10%, and 62.5% vs 14.6%, respectively). The efavirenz discontinuation hazard ratio (HR) was
3.14 (95% confidence interval (CI): 1.35–7.33, P 5 .008). The atazanavir discontinuation HR was 9.13 (95% CI:
3.38–24.69, P , .0001).
Conclusions. Several pharmacogenetic markers identify individuals at risk for early treatment discontinu-
ation. These markers should be considered for validation in the clinical setting.
Pharmacogenetic research has focused on un-
derstanding the mechanisms of adverse drug reactions
(ADR) and on finding biomarkers that identify people
at risk, with the aims of decreasing the number of ad-
verse drug reactions and increasing drug efficacy. In
human immunodeficiency virus (HIV) therapeutics,
pharmacogenetics has been pursued because of the
prevalence of toxicity [1, 2], the long-term nature of
treatment, and the complexity inherent in a multidrug
therapy that could benefit from predictive tools to
identify the drug combination most likely to be tolerated
and effective. Treatment decisions at the initiation of
a first-line antiretroviral therapy (ART) in treatment-
naive individuals are mostly based on CD4 T cell counts,
viremia, symptoms, comorbidities, and analysis of pri-
mary drug resistance. Unfortunately, up to 45% of in-
dividuals discontinue or change treatment during the
first year of ART [3, 4], frequently due to poor treatment
tolerance [4–6].
For abacavir, a randomized prospective trial con-
firmed the value of genetic assessment before prescrip-
tion to avoid hypersensitivity drug reactions [7]. Similar
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information regarding the potential for a pharmacogenetic-
driven intervention does not exist for other ART drugs. How-
ever, there is an increasing body of literature on genes and
genetic markers that may relate to toxicity and or to pharma-
cokinetics of the drug. This includes extensive data on the
pharmacokinetics/genetics of efavirenz, with some indication
that drug levels may associate with central nervous system
toxicity (CYP2B6, CYP2A6, and CYP3A4) [8–11]. Data from
genome-wide association studies on dyslipidemia in the general
population predict ritonavir-boosted protease inhibitor–
associated dyslipidemia (APOA5, CET, DOCK7, GCKR, LPL,
and TRIB1) [12, 13], and there are also genetic predictors of
lopinavir drug levels [14, 15]. Atazanavir-associated hyper-
bilirubinemia is associated with alleles of UGT1A1 [16], and has
been reported in association with alleles of ABCB1 (MDR1) [17]
andNR1I2 (PXR) [18]. There is early information on the genetic
basis of tenofovir tubulopathy (ABCC2, ABBC4) [19, 20].
Most of the above genetic markers are convincingly associated
with an intermediate phenotype (ie, laboratory abnormality),
which may or may not translate into symptoms and signs that
lead to clinical actions such as treatment discontinuation. We
hypothesized that if any of the markers presented above con-
tribute to intolerance or toxicity, they would predict treatment
modification or discontinuation. Therefore, this study aims to
evaluate the association of recognized and proposed genetic
predictors of toxicity or elevated drug levels with time to
treatment discontinuation during the first year of first-line ART.
As the study is retrospective, and the genotype was obtained
a posteriori, it can be considered an unbiased assessment of
genetic association with treatment discontinuation.
METHODS
Study Design and Population
In the Swiss HIV Cohort Study (SHCS, http://www.shcs.ch)
database, clinical and laboratory information were collected
prospectively on standardized questionnaires through a semi-
annual structured interview and a set of prespecified biological
analyses (The Swiss HIV Cohort Study [21]). Eligible study
participants were all ART naive, starting one of the study
medications (n 5 688) between January 2004 and December
2007, and had at least 2 regular follow-up visits within
18 months after treatment initiation. Study ART included te-
nofovir or abacavir, 3TC or FTC, associated with lopinavir or
atazanavir boosted with ritonavir (r) or efavirenz. Participant
selection process was performed with Stata (version 10, Stata-
Corp LP). The SHCS Genetics Project was approved by the
ethics committees of all participating centers, and participants
gave written informed consent for genetic testing. As this lab-
oratory has been active in the description of associations of
genetic markers with efavirenz pharmacokinetics [9–11, 22],
lopinavir/r lipid metabolism and pharmacokinetics [13, 23], and
atazanavir hyperbilirubinemia [16], we identified patients that
could have been included in such previous studies. Only 1 of 272
individuals receiving efavirenz, 20 of 184 individuals receiving
lopinavir/r, and none of 121 individuals receiving atazanavir had
contributed to previous studies in this laboratory.
We defined a discontinuation episode as the first event of stop
of each individual drug, whether the event included discontinu-
ation of 1 or more drugs in the combination ART. At the time of
treatment discontinuation, SHCS physicians are requested to fill
in limited information that codes the reason for discontinuation.
Codes are available for the following categories: treatment failure
(virological), drug-associated toxicity (which includes coding for
dyslipidemia, hypersensitivity reaction, gastrointestinal, liver,
central nervous system, and kidney toxicity, and other toxicities),
patient decision, physician decision, and other. Efavirenz dose
reduction and the introduction of lipid-lowering agents in pa-
tients taking lopinavir/r were also considered as study events,
and were coded as drug-related treatment modifications.
Genotyping
On the basis of existing knowledge [24] and recent publications
[13–15, 18, 20], 23 genetic markers in 15 genes were included in
the study (Table 1). Markers were genotyped using the Veracode
technology (Illumina) with the exception of the UGT1A1 pro-
moter variants (number of TA repeats in the TATA box associated
with hyperbilirubinemia), which were analyzed by sequencing.
Genetic Risk and Scores
For each drug, we assessed the contribution of each independent
allele (Table 1). When supported by the literature, we also as-
sessed their joint contribution in a genetic score. Genetic scores
were established a priori based on literature by using an additive
model [25] (Table 1).
Data Analyses
Rates of ART discontinuation were compared between in-
dividuals with and without genetic risk markers using Cox
proportional hazards regression models. The nongenetic pre-
dictors included: age (stratified in 3 categories: ,40, 40–49,
and .50 years), body weight (stratified in 4 categories: ,60,
60–69, 70–79, and .80 kg), sex, ethnicity (Caucasian, African,
Asian, Hispanic, and other), CD4 T cell count (in 100-cell strata)
and viral RNA concentration (log10 transformed) at the time
of starting ART (baseline), transmission risk group (men who
have sex with men [MSM], heterosexual, blood, injection drug
user [IDU], other, and unknown), year of starting ART (2004,
2005, 2006, and 2007), ART regimen, center, and pregnancy
status. Markers with potential prognostic value after univari-
able analyses were included in a multivariable Cox model for
association with the ART treatment discontinuation during the
1-year follow-up period. The proportional hazards assumptions
were assessed for all models using Schoenfeld residuals. We used
Stata software, version 11 (StataCorp LP) for analyses.
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Table 1. Genes, Genetic Variants, and Genetic Scores. Panel A: 23 genetic variants were selected on the basis of literature, and association
with an intermediate pharmacokinetic or toxicity phenotype. Panel B: description of genetic risk scores. The numbers represent the count of
variant alleles. Scores for efavirenz and lopinavir/r have been previously described. The atazanavir score has been explored post hoc
A.
Drug Gene
Genetic variant
(rs number)a
Genetic variant
change
Minor allele
(nomenclature)
Expected minor
allele effect Reference
TDF ABCC2 rs2273697 G.A A Risk [19]
ABCC2 rs717620 C.T T Protective [19, 20]
ABCC4 rs899494 C.T T Risk [19]
EFV CYP2A6 rs28399433 T.G G (*9) Risk [10, 11]
CYP2B6 rs3745274 G.T T (*6) Risk [8, 9, 22]
rs35303484 A.G G (*11) Risk
rs35979566 T.A A (*15) Risk
rs28399499 T.C C (*18) Risk
CYP3A4 rs4646437 C.T T Risk [10, 11]
LPV APOA5 rs3135506 C.G G Risk [12, 13]
rs662799 T.C C Risk
CETP rs708272 G.A A Protective
DOCK7 rs1748195 C.G G Protective
GCKR rs780094 C.T T Risk
LPL rs6586891 A.C C Risk
rs328 C.G G Protective
TRIB1 rs17321515 A.G G Protective
ABCC2 rs717620 C.T T Protective [14]
CYP3A rs6945984 T.C C Risk [14]
SLCO1B1 rs11045819 C.A A (*4) Protective [14]
rs4149056 T.C C (*5) Risk [14, 15]
ATV ABCB1 rs1045642 C.T T Risk [17]
NR1I2 rs 2472677 T.C C Protective [18]
UGT1A1 rs8175347 A(TA)6TAA . A(TA)5, 7 or 8TAA (TA)7 (*28) Risk [16]
(TA)5 (*36) Protective
(TA)8 (*37) Risk
B.
Efavirenz CYP2B6/2A6/3A4 six-group genetic score
Genes Genetic variant Score 1 Score 2 Score 3 Score 4 Score 5 Score 6
CYP2B6 rs3745274 (*6)
rs35303484 (*11)
rs35979566 (*15)
rs28399499 (*18)
0 0 1 1 2 2
CYP2A6 rs28399433 (*9) 0 1 to 4 0 1 to 4 0 1 to 4
CYP3A4 rs4646437
Lopinavir Hypertriglyceridemia additive genetic scoreb,c
Genes Genetic variant Score 1 Score 2 Score 3
Risk variant -4 to -2 -1 to 0 11 to 14
APOA5 rs3135506
rs662799
GCKR rs780094
LPL rs6586891
Protective variant
DOCK7 rs1748195
TRIB1 rs17321515
CETP rs708272
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RESULTS
Demographic and Genetic Characteristics of Participants
Of a total of 668 patients starting ART with the study medication
(ie, tenofovir, efavirenz, lopinavir/r, or atazanavir), 577 in-
dividuals were successfully genotyped and included in the
analysis. Reasons for exclusion included an incomplete genetic
consent (n 5 5), unavailable biological material (n 5 7), un-
successful genotyping (n 5 2), and samples that were not in-
cluded because the standard size of the genotyping array was
reached (n5 77). The 91 individuals not included in the analysis
were comparable in age, sex, and ethnicity to those included, but
more likely to receive efavirenz (86% vs 47%) because such
samples were preferentially excluded once the array capacity was
reached. Most of the participants were Caucasian (80%) and
men (73%). ART regimen included tenofovir/emtricitabine or
lamivudine (n 5 500) or abacavir/emtricitabine or lamivudine
(n 5 77), and efavirenz (n 5 272) or lopinavir/r (n 5 184) or
atazanavir boosted with ritonavir (n 5 121). Age was median
44 years (interquartile range [IQR] 37–50 years). The presumed
mode of HIV transmission was men who had sex with men
(44.4%), heterosexual (40.6%), injection drug users (11.4%),
and unknown/other (3.6%). Baseline (ART start) CD41 T cell
count was median 209 cells/lL (IQR: 125–282 cells/lL), and
HIV viral load was median 4.9 log copies/mL (IQR: 4.4–5.4 log
copies/mL). The exact time span of the study was from 5 January
2004 (earliest ART initiation) to 4 November 2008 (last regis-
tered follow-up). The median follow-up time (interval between
ART initiation date and last registered follow-up date) was
618 days (IQR: 463–914 days). A total of 53 (9%) participants
were lost for follow-up during the first year after ART initiation,
and were censored. Distribution of alleles and genotypes were
comparable for the populations receiving or not receiving the
drug concerned by each specific genetic variant, with the
exception of CYP2B6 rs28399499, a genetic variant only present
in Africans. A total of 190 (33%) individuals discontinued ART;
in 117 instances, this concerned a single drug; in 62 instances,
two or more components of the regimen; and 11 individuals
stopped 2 or more drugs at different times.
Genetic Risk and Discontinuation of Tenofovir
Among 500 patients receiving tenofovir, 70 (14%) discontinued
treatment in the first year. The various genetic variants evaluated
did not present a statistically significant association with rates of
treatment discontinuation (Table 2). In the first year, individuals
carrying 1 (CT) or 2 (TT) risk alleles of ABCC4 rs899494 dis-
continued tenofovir with cumulative rates of 19% and 7%, re-
spectively, compared with 13% among individuals without the
genetic risk allele (CC): adjusted hazard ratio (HRa) (CT) 1.60
(95% CI: 0.95–2.70), Pa 5 .080; and HRa (TT) 0.38 (95% CI:
0.05–2.85), Pa 5 .345, respectively (Figure 1A). Individuals
carrying 1 (GA) or 2 (AA) risk alleles of ABCC2 rs2273697
variant discontinued tenofovir with cumulative rates of 12.26%
and 28.60%, respectively, compared with 14.23% among in-
dividuals without the genetic risk allele (GG): HRa (GA) 0.77
(95% CI: 0.44–1.36), Pa 5 .371; and HRa (AA) 1.39, (95% CI:
0.58–3.40), Pa 5 .473, respectively (Figure 1B). We did not
observe differences in discontinuation rates associated with
LPL rs328
Pharmacokinetic genetic scored
Score -2 Score 0 Score 12
SLCO1B1 rs11045819 (*4) 2 0 or 1 0
rs4149056 (*5) 0 ,2 >2
ABCC2 rs717620,
CYP3A rs6945984
Atazanavir UGT1A1/ABCB1 additive genetic score
Genes Genetic variant Score 0 Score 1 Score 2 Score 3 Score 4
UGT1A1 rs8175347 (*28, *37) 0 0 1 1 0 2 1 2 2
ABCB1 rs1045642 0 1 0 1 2 0 2 1 2
NOTE. ABCB1: ATP-binding cassette, subfamily B (MDR/TAP), member 1; ABCC2 and 4: ATP-binding cassette subfamily C members 2 and 4; APOA5:
apolipoprotein A5; ATV: atazanavir; CETP: cholesteryl ester transfer protein; CYP2A6, 2B6, and 3A4: Cytochrome P-450 2A6, 2B6, and 3A4; DOCK7: dedicator of
cytokinesis 7; EFV: efavirenz; GCKR: glucokinase (hexokinase 4) regulator; HCP5: HLA complex P5; LPL: lipoprotein lipase; LPV: lopinavir/r; NR1I2: nuclear receptor
subfamily 1, group I, member 2; SLCO1B1: solute carrier organic anion transporter family, member 1B1; TDF: tenofovir; TRIB1: tribbles homolog 1 (Drosophila);
UGT1A1: UDP glucuronosyltransferase 1 family polypeptide A1.
a The rs numbers are the accession numbers in the National Center for Biotechnology Information single-nucleotide polymorphism database, dbSNP.
b Described previously by Arab-Alameddine et al. in the study of efavirenz plasma levels [11].
c Described previously by Rotger et al. The numbers represents the score values resulting from adding and subtracting the number of variant alleles of the risk and
protective genetic variants, respectively [13].
d Described previously by Lubomirov et al. in the study of lopinavir plasma levels; patients with Score -2 have low plasma levels, and with Score 12 have high
plasma levels compared to the Score 0 [14].
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ABCC2 rs717620 genotypes (Figure 1C). The final Cox analysis
identified body weight as significant covariable. Individuals with
body weight lower than 60 kg or between 60 and 69 kg had
higher risk of discontinuation (HRa 5 2.71, 95% CI: 1.14–6.44,
Pa 5 .024; and HRa 5 2.43, 95% CI: 1.13–5.26, Pa 5 .024,
respectively) compared with the reference group (70–79 kg).
Genetic Risk and Discontinuation of Efavirenz
Among 272 patients receiving efavirenz, 81 discontinued
treatment in the first year with a cumulative rate of 30%. For 3
individuals, the event was a dose reduction rather than full
discontinuation; 2 of the 3 had neuropsychological toxicity as
the stated reason for dose reduction. The various genetic
variants and scores were associated with different rates of
treatment discontinuation (Table 2). Consistent with the
known pharmacokinetic associations, the data indicated that
loss of CYP2B6 function (homozygocity, decrease/loss of
function alleles) with a concomitant decrease of function in
accessory metabolic pathways (decrease/loss of function al-
leles of CYP2A6 and/or CYP3A4) was associated with a higher
Table 2. Detailed Results From the Cox Regression Models for Each Drug
Drug SNP/score
Genotype/score
group
Adjusted hazard
ratio (95% confidence
interval)
Adjusted
P value
Cumulative
discontinuation
rate (%)
Tenofovir ABCC4 rs899494 CC (0) 1 (Reference) — 12.66
CT (1) 1.60 (0.95–2.70) .080 19.00
TT (2) 0.38 (0.05–2.85) .345 6.70
ABCC2 rs2273697 GG (0) 1 (Reference) — 14.23
GA (1) 0.77 (0.44–1.36) .371 12.26
AA (2) 1.39 (0.58–3.40) .473 28.60
ABCC2 rs717620 CC (0) 1 (Reference) — 15.30
CT (1) 0.85 (0.48–1.52) .582 11.80
TT (2) 1.15 (0.34–3.87) .815 13.04
Efavirenz CYP2B6/2A6/3A4 score Score 1 1 (Reference) — 32.30
Score 2 0.85 (0.43–1.70) .648 28.90
Score 3 0.57 (0.28–1.17) .125 22.00
Score 4 0.61 (0.27–1.38) .234 29.90
Score 5 0.86 (0.24–3.10) .820 23.00
Score 6 2.10 (0.70–6.01) .185 71.15
CYP2B6/2A6/3A4 score
(dichotomized)
Score 1–5 1 (Reference) — 28.10
Score 6 3.14 (1.35–7.33) .008 71.15
Lopinavir Hypertriglyceridemia
additive score
Score 1 1 (Reference) — 30.00
Score 2 0.99 (0.52–1.88) .967 35.90
Score 3 1.27 (0.61–2.61) .523 36.40
Pharmacokinetic score Score -2 1 (Reference) — 20.00
Score 0 2.03 (0.26–15.87) .499 34.00
Score 12 2.15 (0.27–17.27) .473 36.00
Atazanavir UGT1A1 rs8175347 *1/*1 1 (Reference) — 14.60
*1/*28, *37 1.97 (0.77–5.03) .158 23.80
*28/*28, *37 9.13 (3.38–24.69) <.0001 62.50
NR1I2 rs2472677 TT (0) 1 (Reference) — 21.80
TC (1) 1.42 (0.61–3.26) .413 28.90
CC (2) 1.1 (0.32–3.67) .905 22.30
ABCB1 rs1045642 CC (0) 1 (Reference) — 21.30
CT (1) 1.54 (0.55–4.32) .416 22.50
TT (2) 2.33 (0.84–6.50) .105 34.80
UGT1A1/ABCB1
additive score
Score 011 1 (Reference) — 14.61
Score 2 2.53 (0.95–6.70) .062 29.16
Score 3 5.44 (1.86–15.90) .002 39.40
Score 4 7.22 (1.90–27.50) .004 57.14
NOTE. SNP: single-nucleotide polymorphism.
The nongenetic covariables evaluated and included when appropriate included body weight, sex, ethnicity, CD4 T cell count and viral RNA concentration,
transmission category, year of starting ART, treatment regimen, clinical center, and pregnancy status.
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risk of discontinuation (Figure 2). Individuals with the
highest genetic risk score (score 6) discontinued efavirenz
more frequently than individuals with lower genetic
risk scores, with cumulative rates of 71.15% vs 28.10%
(HRa5 3.14, 95% CI: 1.35–7.33, Pa5 .008) (Table 2). Among
covariates, sex showed an independent statistically significant
effect on efavirenz discontinuation, with women showing
a higher risk (HRa 5 3.08, 95% CI: 1.62–5.85, Pa 5 .001),
consistent with published estimates [26–28].
Genetic Risk and Discontinuation of Lopinavir
Among 184 patients receiving lopinavir, 60 discontinued
treatment in the first year, with a cumulative rate of 34%.
Eight genetic variants associated with hypertriglyceridemia
[12, 13] were evaluated individually and in unweighted ad-
ditive scores. Only CETP rs708272 G.A genotypes displayed
when assessed in isolation, assuming a dominant genetic
model (GG vs GA 1 AA), a marginally significant protection
from early treatment discontinuation (HRa 5 0.60, 95%
CI: 0.35–1.01, Pa 5 .056). The unweighted 3-level additive
score (Table 1) did not show an association of genetic variants
with early treatment discontinuation (Figure 3A and Table 2).
Separately, we assessed the contribution of 4 genetic variants
in 3 genes that are associated with lopinavir/r pharmacokinetics
[14]. None of the 4 single-nucleotide polymorphisms (SNPs)
were individually associated with treatment discontinuation.
A 3-level genetic score (Table 1) did not identify a significant
statistical association with treatment discontinuation, although
we observed low rates of treatment discontinuation among the
rare individuals homozygous for SLCO1B1*4 (rs11045819),
a gain-of-function variant associated with low lopinavir/r levels
(Figure 3B). No other covariates were associated with lopinavir/r
discontinuation at 1 year.
0 60 120 180 240 300 360
0
10
20
30
40
50
60
70
80
90
100
0 (Ref.)
1 (Pa=0.080)
2 (Pa=0.345)
347
138
No. at Risk
0
1
336
130
328
123
323
120
305
115
290
108 100
270
152 14 14 14 14 12 11
A
Time to discontinuation (days)
TD
F 
di
sc
on
ti
nu
at
io
n 
(%
)
0 60 120 180 240 300 360
0
10
20
30
40
50
60
70
80
90
100
0 (Ref.)
1 (Pa=0.371)
2 (Pa=0.473)
328
151
No. at Risk
0
1
314
146
303
145
298
144
283
135
270
125 118
250
212 20 17 15 15 14 13
B
Time to discontinuation (days)
TD
F 
di
sc
on
tin
ua
ti
on
 (
%
)
0 60 120 180 240 300 360
0
10
20
30
40
50
60
70
80
90
100
0 (Ref.)
1 (Pa=0.582)
2 (Pa=0.815)
340
137
No. at Risk
0
1
325
134
314
130
306
130
289
123
273
118 108
255
232 21 21 21 21 19 18
C
Time to discontinuation (days)
TD
F 
di
sc
on
ti
nu
at
io
n 
(%
)
Figure 1. Genetic risk of tenofovir discontinuation at 1 year. Cumulative rates of discontinuation for 500 participants stratified by ABCC4 and ABCC2
genetic variants: (A) by ABCC4 rs899494 genotypes CC (0), CT (1), and TT (2); (B) by ABCC2 rs2273697 genotypes GG (0), GA (1), and AA (2); and (C) by
ABCC2 rs717620 genotypes CC (0), CT (1), and TT (2). Pa, covariate adjusted P value, estimated from Cox regression models.
NOTE. CC: individuals without the genetic risk allele ABCC4 rs899494; CT: individuals carrying 1 risk allele ABCC4 rs899494; TT: individuals carrying 2 risk
alleles ABCC4 rs899494; GG: individuals without genetic risk allele ABCC2 rs2273697; GA: individuals carrying 1 genetic risk allele ABCC2 rs2273697; AA:
individuals carrying 2 genetic risk alleles ABCC2 rs2273697.
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Genetic Risk and Discontinuation of Atazanavir
Among 121 patients receiving atazanavir boosted with ritonavir,
30 discontinued treatment in the first year with a cumulative
rate of 25%. Homozygocity of decreased function UGT1A1
alleles (*28/*28 or *28/*37) was associated with risk of treatment
discontinuation (HRa 5 9.13, 95% CI: 3.38–24.69, Pa , .0001)
(Figure 4A and Table 2). There was a statistically nonsignificant
increase in risk associated with the carrier state (HRa 5 1.97,
95% CI: 0.77–5.03, Pa 5.158). First-year cumulative rates of
treatment discontinuation were 62.5% for homozygous, 23.8%
for heterozygous, and 14.6% for noncarrier individuals. No
other covariates were associated with atazanavir discontinuation
at 1 year. We explored whether differences in rates of discon-
tinuation across centers (varying from 0% to 47%) could reflect
center-specific policy and threshold of response to the specific
toxicity. For the 4 centers prescribing atazanavir to more than 10
individuals, there was a statistically significant correlation be-
tween discontinuation rates and frequency of UGT1A1*28
homozygocity (r2 5 0.858, P 5.048).
Two other studies have described the association of variants of
NR1I2 and ABCB1 genes to atazanavir pharmacokinetics and/or
hyperbilirubinemia [17, 18]. We did not observe an association of
NR1I2 variant and treatment discontinuation rates (Figure 4B).
Variant rs1045642 G.A of ABCB1 was associated with different
rates of treatment discontinuation (Figure 4C). Homozygous
individuals had an HRa of 2.33 (95% CI: 0.84–6.50), although the
results did not reach statistical significance (Pa 5.105). The in-
clusion of ABCB1 variant in an additive UGT1A1/ABCB1 genetic
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Figure 3. Genetic risk of lopinavir discontinuation at 1 year. Cumulative rates of discontinuation for 184 participants stratified by hypertriglyceridemia
(A) and pharmacokinetic (B) genetic scores. Pa, covariate adjusted P value.
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Figure 2. Genetic risk of efavirenz discontinuation at 1 year. Cumulative rates of discontinuation for 272 participants stratified by CYP2B6, CYP2A6, and
CYP3A4 genetic variants by six-group genetic score (A) and by dichotomized genetic score. Pa, covariate adjusted P value (B).
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score (Table 1) stratified the risk of discontinuation conferred by
UGT1A1 variants (Figure 4D). In the joint analysis, the cumu-
lative discontinuation rate ranged from 29% to 57% across
genetic risk scores. However, these UGT1A1/ABCB1 genetic
score–containing Cox regression model did not reduce the
Akaike information criterion compared with the model
containing only UGT1A1 (262.93 vs 257.40, respectively).
Early Discontinuation
Eleven (2%) of the participants discontinued treatment within
the first week—the earliest discontinuation was on day 2. Six
patients discontinued tenofovir, none were homozygous for the
risk allele of ABCC2 rs2273697. Four patients discontinued
efavirenz; none had a genetic risk score of 6. Three patients
discontinued lopinavir/r; 1 had a pharmacokinetic genetic risk
score of 12, and 2 had a dyslipidemia genetic risk score of 3.
Two patients discontinued atazanavir; both were homozygous
for the risk allele of UGT1A1 rs8175347.
Evaluation of Coded Reasons for Discontinuation
During routine care, the SHCS physician indicates a coded
reason for discontinuation at the time of treatment stop or
modification. Retrospective assessment of the codes for the
overall study identified the following categories as main reasons:
drug-associated toxicity (15%), physician decision (8%), and
patient decision (6%), which are in accordance with previously
reported reasons for treatment change [4]. The reported reasons
for treatment discontinuation are presented for each drug in
Table 3. Based on the data presented in the previous sections, we
used a score of 6 to define efavirenz genetic risk. For atazanavir,
we defined risk by the simpler UGT1A1-based risk (promoter
allele *28/28 or *28/*37) based on the Akaike information
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Figure 4. Genetic risk of atazanavir discontinuation at 1 year. Cumulative rates of discontinuation for 121 participants stratified by UGT1A1, NR1I2, and
ABCB1 genetic variants: (A) by UGT1A1 rs8175347 genotypes *1/*1, *1/*28 or *37, and *28/*28 or *37; (B) by NR1I2 rs2472677 genotypes TT (0), CT (1),
and CC (2); (C) by ABCB1 rs1045642 genotypes CC (0), CT (1), and TT (2); (D) by UGT1A1/ABCB1 additive genetic score. Pa, covariate adjusted P value.
NOTE. TT: individuals carrying 2 risk alleles ABCC4 rs899494; CT: individuals carrying 1 risk allele ABCC4 rs899494; CC: individuals without the genetic
risk allele ABCC4 rs899494.
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Table 3. Reasons for Drug Discontinuation According to the Coding Provided by the Treating Physician.
Tenofovira Efavirenzb Lopinavir/rc Atazanavird
Reason for drug
discontinuation
Population
with
genetic
risk, n 5 21
Discontinuation
events (%)
Population
without
genetic
risk, n 5 479
Discontinuation
events (%) P e
Population
with genetic
risk, n 5 13
Discontinuation
events (%)
Population
without
genetic risk,
n 5 259
Discontinuation
events (%) P e
Population
with HTG
genetic risk,
n 5 45
Discontinuation
events (%)
Population
without HTG
genetic risk,
n 5 139
Discontinuation
events (%) Pe
Population
with genetic
risk, n 5 18
Discontinuation
events (%)
Population
without
genetic risk,
n 5 103
Discontinuation
events (%) P e
Virological treatment
failure
0 (0.00) 6 (1.25) 1 0 (0.00) 15 (5.79) 1 0 (0.00) 0 (0.00) 1 0 (0.00) 0 (0.00) 1
Drug associated
toxicity
3 (14.29) 22 (4.59) .081 8 (61.54)f 32 (12.36) <.0001 6 (13.33) 12 (8.63) .389 6 (33.33) 7 (6.80) .004
Patient decision 1 (4.76) 22 (4.59) 1 1 (7.69) 8 (3.09) .361 5 (11.11) 11 (7.91) .545 2 (11.11) 6 (5.83) .339
Physician decision 0 (0.00) 12 (2.51) 1 0 (0.00) 12 (4.63) 1 5 (11.11) 20 (14.39) .803 2 (11.11) 5 (4.85) .279
Other 2 (9.52) 2 (0.42) .009 0 (0.00) 5 (1.93) 1 0 (0.00) 1 (0.72) 1 1 (5.56) 1 (0.97) .274
NOTE. Based on the data presented in the text, we used score 6 to define efavirenz genetic risk. For atazanavir, we defined risk by the simpler UGT1A1-based risk (promoter allele *28/28 or *28/*37) based on the Akaike
information criterion. Because there is no defined genetic risk for treatment discontinuation of tenofovir, homozygocity ABCC2 rs2273697 was further explored for the analysis of reasons for treatment discontinuation. For
lopinavir/r, we considered the genetic risk for dyslipidemia as surrogate for the analysis of reasons for treatment discontinuation.
a Population with (AA or GA) and without (GG) genetic risk of tenofovir discontinuation according to the ABCC2 rs2273697 variant genotypes.
b Population with (score 6) and without (scores 1 to 5) genetic risk of efavirenz discontinuation according to the CYP2B6/2A6/3A genetic score.
c Population with (score 3) and without (scores 1 and 2) genetic risk of lopinavir/r discontinuation according to the risk of hypertriglyceridemia (HTG) additive genetic score.
d Population with (*28/*28 or *28/*37) and without (*1/*1, *1/*28, or *1/*36) genetic risk of atazanavir discontinuation according to the UGT1A1 rs8175347 variant genotypes.
e Fisher exact test P value.
f Includes 3 instances of treatment dose modification.
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criterion. There is no defined genetic risk for treatment dis-
continuation for tenofovir or lopinavir/r. For tenofovir, we ex-
plored whether the trend observed for ABCC2 rs2273697 was
further supported in the clinical analysis. For lopinavir/r, we
considered the genetic risk for dyslipidemia as surrogate for the
genetic risk of treatment discontinuation. The code ‘‘drug-
associated toxicity’’ was invoked in 62% of instances when
efavirenz was discontinued among individuals with a genetic
risk versus 12% in those without (P , .0001). The code ‘‘drug-
associated toxicity’’ was invoked in 33% of instances when
atazanavir was discontinued among individuals with a genetic
risk versus 7% in those without (P 5 .004).
DISCUSSION
This study tested the hypothesis that biological consequences
of genetic variants will, if significant or severe, lead to treat-
ment discontinuation, a well defined clinical outcome.
Among 23 genetic variants included in the study, those in
CYP2B6, 2A6, and 3A4 previously associated with plasma
levels of efavirenz, and those in UGT1A1 previously associated
with atazanavir-induced hyperbilirubinemia were also asso-
ciated with early treatment discontinuation. The retrospective
study was not designed to assess other clinical endpoints such
as specific toxicities; however, assessment of the codes used in
routine care to indicate the reasons for treatment discontin-
uation convincingly associated genetic risk to toxicity for
those 2 drugs.
Thus, the study suggests that assessment of the genetic markers
could lead to improved prescription of atazanavir and efavirenz.
Unconjugated hyperbilirubinemia, the main adverse effect of
atazanavir, is widely considered as irrelevant in clinical care [29].
However, despite the reversibility and the absence of clinical
consequences of hyperbilirubinemia, 2 of 3 individuals homo-
zygous for the UGT1A1 promoter variant discontinued ataza-
navir in the present study. Differences in rates of discontinuation
across centers reflected the frequency of homozygous individuals
receiving the drug. Overall, 10% of Caucasians carry this genetic
risk, but its frequency varies across ethnic groups [30].
The basis of treatment discontinuation of efavirenz is more
complex. While the genetic determinants of efavirenz blood
levels are by now well understood [10, 11], there is no consensus
as to whether high drug levels are associated with neuro-
psychotoxicity, or on the usefulness of therapeutic drug moni-
toring and dose adjustment [31]. These considerations
notwithstanding, the study suggests that treatment discontinu-
ation correlates with decreased metabolism of efavirenz, and
that the loss of the primary metabolic pathway, CYP2B6, is
necessary but not sufficient [32] for an increased rate in efa-
virenz discontinuation. Extremely high plasma drug levels of
efavirenz results from loss of both primary (CYP2B6) and ac-
cessory (CYP3A4 and/or CYP2A6) metabolic pathways [10].
Consistent with such pharmacokinetic data, individuals that
have loss of accessory metabolisms in the context of homozy-
gous loss of function of CYP2B6 present the highest risk of
treatment discontinuation. As pointed out for atazanavir, these
data question the interest to initiate efavirenz in individuals with
the genetic risk if two-thirds of them will subsequently dis-
continue the drug.
The study included tenofovir despite the paucity of genetic
data associated with toxicity for this drug. We analyzed the
genetic variants as proposed by Izzedine et al. [19] in a study of
13 individuals with tubular dysfunction on tenofovir, and by
Rodriguez-Novoa et al. [20] in a study of 115 HIV-infected
patients of whom 19 had tubular dysfunction. The current study
suggests a possible association of rs2273697 G.A variant in
ABCC2 with higher rates of drug discontinuation. The SHCS
database did not allow for detailed analysis of the reasons for
discontinuation in these individuals; in particular, for renal
function (see below). Thus, the data on rs2273697 G.A should
be considered preliminary; additional discovery efforts on the
genetics of tenofovir are needed.
The case of lopinavir is a pertinent example of how
a well-documented association of genetic variants and a lab-
oratory phenotype (dyslipidemia) with potential long-term
consequences—cardiovascular disease—may not translate
into short-term clinical decisions. We did not document an
association between the proposed risk score and treatment
discontinuation or introduction of a lipid-lowering agent.
However, the most appropriate clinical endpoint here would
have been the actual laboratory data (reaching clinically rel-
evant cut-offs of dyslipidemia) [12]. The patient carrying the
genetic risk could be prescribed an alternative drug on that
basis. Prediction of dyslipidemia will improve with the
increasing availability of genetic markers [13, 33].
This study did not include abacavir hypersensitivity because
clinical testing for HLA*B5701 was introduced during the study
period. We did, however, notice that the allelic frequency for the
risk marker was lower in patients that received abacavir than
among those that did not (data not shown)—confirming that
the patients were increasingly screened before treatment initia-
tion. Another relevant observation of the present study is that
although genetic predisposition to toxicity might lead, through
poor adherence, to virological treatment failure, there were few
(n 5 15) instances coded as virological treatment failure, and
none among participants with the genetic risk marker. The
current analysis did not consider drug adherence; its inclusion
would have been informative.
This study should be considered as a pilot analysis that can
provide data for power calculation, and support further dis-
covery efforts toward identification of additional genetic
markers. Thereafter, a prospective clinical trial should ideally
formalize the analysis, and provide the basis for measuring the
cost effectiveness of this approach [34].
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